RAAPID makes the code show its work

A diagnosis can be hiding in plain sight. It might sit halfway through a hospital record, surrounded by medication lists, copied notes and the debris of earlier visits. Finding it takes time. Deciding whether it supports a medical code takes judgment. Explaining that decision to an auditor requires something else again: a trail another person can follow.

RAAPID has built its business around that third task. The Louisville company sells artificial intelligence for risk adjustment, the work of representing patients’ health conditions accurately in payment systems. Its interesting proposition is that a coding recommendation should arrive carrying its evidence. A reviewer should be able to ask why, then inspect the answer.

The trouble with finding more

Consider the incentives. An overlooked condition can leave a patient’s documented risk incomplete. An unsupported condition creates a different problem. In Medicare Advantage, CMS uses Risk Adjustment Data Validation audits to check whether submitted diagnoses have support in medical records. Unsupported diagnoses can lead to recovery of overpayments. Finding additional codes, by itself, is an inadequate definition of success.

This gives RAAPID a particular place in healthcare software. It serves the people between the clinical record and the payment calculation: coders, compliance reviewers, health-plan teams and clinicians working in value-based care. Its competition includes specialist risk adjustment vendors such as Reveleer and Edifecs, alongside the familiar machinery of manual review and outsourced coding.

The company’s distinction is an emphasis on traceability. Its system can recommend adding a supported diagnosis or removing an unsupported one. That second direction matters. A tool evaluated only on the number of additions has little reason to celebrate a deletion. A team responsible for the accuracy of the finished record has every reason to care.

“Payers are closest to the regulatory fire.”Chetan Parikh · April 2026

A recommendation with its workings attached

RAAPID calls its approach neuro-symbolic AI. The neural component recognizes patterns in messy clinical information. The symbolic component brings structured medical knowledge and relationships into the process. In its January 2025 funding announcement, the company described a knowledge graph with more than four million clinical entities and 50 million relationships.

For the buyer, the useful question is less about the label than the output. Can a reviewer move from a suggested code to the relevant passage and its encounter context? RAAPID organizes evidence around MEAT, a coding shorthand for monitoring, evaluation, assessment and treatment. The software is designed to expose the clinical basis for its suggestions so a person can evaluate them.

The product stretches across three moments. Retrospective review examines existing charts. Prospective review prepares information for an upcoming visit and checks documentation afterward. The audit product organizes records, reviews and responses when evidence must be assembled for scrutiny. Clinical APIs offer another route: organizations can bring coding and extraction capabilities into existing software.

The visit is where a suspicion gets tested

The prospective workflow makes the limits particularly clear. RAAPID describes connecting claims, laboratory results and chart information to surface suspected conditions before a visit. Reviewers curate what reaches the physician. The physician can accept and document a finding or reject it with a reason; post-visit checks compare the resulting chart with the claim.

A suspected condition remains a question for clinical evaluation. Software cannot supply a missing examination or turn an uncertain finding into a documented diagnosis simply by displaying it confidently. The practical benefit is preparation: put relevant evidence in front of the person who can investigate it, within the workflow that person already uses.

Three investors, three sets of questions

RAAPID’s backing reflects the audiences it needs to satisfy. M12, Microsoft’s venture fund, appeared in its January 2025 Series A announcement. UPMC Enterprises joined through an extension announced in March 2026, with plans for co-development. Healthworx, CareFirst’s investment arm, followed in April. Together, those investors bring technology, health-system and payer perspectives to the same product.

The commercial model is enterprise software and services: cloud applications, APIs, coding support and audit assistance. The UPMC announcement also described a procurement advantage for eligible Azure customers, who can apply existing Microsoft Azure Consumption Commitments toward the platform. That may ease purchasing. Integration, access controls and operational responsibility still belong in the buying conversation.

Security is another buying condition. In June 2026, RAAPID announced HITRUST r2 certification for its platform residing on Microsoft Azure East, adding to its reported SOC 2 Type II compliance. Those credentials concern protection of sensitive information. Buyers must separately evaluate whether coding recommendations work for their records and review standards.

Bring your own charts

The performance numbers deserve careful reading. RAAPID’s retrospective page distinguishes 92% out-of-box AI accuracy from 98% final coding accuracy. They describe different stages of the work. Its published efficiency and return figures are company claims, rather than a promise that every customer will reproduce the same economics.

Customer feedback offers a useful early signal. RAAPID reports that all five interviewed respondents in that KLAS spotlight would buy again. The small denominator belongs beside the favorable result. Its public case studies also describe customers mainly by organizational type, including regional plans and provider groups. Treat those accounts as starting points for a reference conversation.

The lesson a buyer can copy is straightforward: test the evidence trail on your own records. Measure what reviewers must correct, what unsupported codes are caught and how much work remains after the AI runs. Poor documentation and awkward integration can erase a speed advantage. The valuable output is a recommendation that another person can examine, question and use.